Vitiligo, New Treatment and Serum s100B

Launched by SOUTH VALLEY UNIVERSITY · Jan 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for vitiligo, a skin condition where patches of skin lose their color, affecting about 2% of people worldwide. The trial is looking at a specific type of medication called a JAK inhibitor, which might help improve the skin condition in patients who have active generalized vitiligo. If you or someone you know has vitiligo that covers more than 5% of the body (not including the hands and feet) and hasn’t used any systemic treatments in the last three months or topical treatments in the last four weeks, they may be eligible to participate.

Participants in this trial can expect to receive the new treatment and be closely monitored by healthcare professionals. The trial is currently recruiting individuals aged between 12 and 75, and it is open to all genders. However, those with certain other skin conditions or serious health issues, as well as pregnant or breastfeeding individuals, will not be able to join. This study is important because it aims to find better ways to manage vitiligo, which can significantly impact a person’s quality of life and self-esteem.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • active generalized vitiligo patients with body surface area involved \>5% excluding hands and feet
• • no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.
• Exclusion Criteria:
• • acrofacial, acral, segmental or mucosal vitiligo
• • patients on another immunosuppressive agent
• • patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo.
• • patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma)
• • Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness.
• • Pregnancy and lactation.